Edgewise Shares Rise Premarket on FDA Fast-Track Designation
By Colin Kellaher
Edgewise Therapeutics shares moved higher in premarket trading Tuesday after the clinical-stage biopharmaceutical company won U.S. Food and Drug Administration fast-track designation for EDG-5506 for the treatment of Duchenne muscular dystrophy.
Shares, which closed Monday at $18.95, were recently up 7.9% to $20.45 in premarket trading.
The Boulder, Colo., company on Tuesday said it is currently conducting a pair of Phase 2 placebo-controlled studies of EDG-5506 in Duchenne, a severe, degenerative muscle disorder.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
The FDA previously granted orphan-drug designation to EDG-5506 for the treatment of Duchenne and Becker muscular dystrophy, rare-pediatric-disease designation for the treatment of Duchenne, and fast-track designation for the treatment of Becker.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 13, 2024 08:49 ET (13:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying